CR11581A - Composiciones en forma de comprimidos bucodispersables de temazepan - Google Patents

Composiciones en forma de comprimidos bucodispersables de temazepan

Info

Publication number
CR11581A
CR11581A CR11581A CR11581A CR11581A CR 11581 A CR11581 A CR 11581A CR 11581 A CR11581 A CR 11581A CR 11581 A CR11581 A CR 11581A CR 11581 A CR11581 A CR 11581A
Authority
CR
Costa Rica
Prior art keywords
compositions
temazepan
tablets
bucodispersable
cbd
Prior art date
Application number
CR11581A
Other languages
English (en)
Inventor
Gopi Venkatesh
Jin-Wang Lai
Vivek Purohit
James Clevenger
Original Assignee
Eurand Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40798736&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR11581(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eurand Inc filed Critical Eurand Inc
Publication of CR11581A publication Critical patent/CR11581A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Las composiciones de la presente invencion son composiciones en forma de comprimidos bucodispersables que comprenden una cantidad terapeuticamente eficaz de al menos un farmaco como el temazepan, un 0.5-3% de un polimero aglutinante CBD, un alcohol de azucar y/o sacarido, y un disgregante.
CR11581A 2007-12-21 2010-07-21 Composiciones en forma de comprimidos bucodispersables de temazepan CR11581A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1593107P 2007-12-21 2007-12-21

Publications (1)

Publication Number Publication Date
CR11581A true CR11581A (es) 2010-10-11

Family

ID=40798736

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11581A CR11581A (es) 2007-12-21 2010-07-21 Composiciones en forma de comprimidos bucodispersables de temazepan

Country Status (10)

Country Link
US (1) US20090169620A1 (es)
KR (1) KR20100103844A (es)
CN (2) CN105496978A (es)
AR (1) AR069875A1 (es)
BR (1) BRPI0821761A2 (es)
CL (1) CL2008003827A1 (es)
CO (1) CO6280465A2 (es)
CR (1) CR11581A (es)
RU (2) RU2524638C2 (es)
WO (1) WO2009086046A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
EP2328558A2 (en) * 2008-08-08 2011-06-08 McNeil-PPC, Inc. Use of sucralose as a granulating agent
WO2010137027A1 (en) * 2009-05-27 2010-12-02 Hetero Research Foundation Solid oral dosage forms of lamivudine
EP2440210A4 (en) 2009-06-12 2014-01-29 Meritage Pharma Inc METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES
KR20150043548A (ko) * 2009-10-01 2015-04-22 앱탈리스 파마테크, 인코포레이티드 경구 투여용 코르티코스테로이드 조성물
WO2011058498A2 (en) * 2009-11-10 2011-05-19 North-West University Method for increasing the solubility of a transcriptase inhibitor composition
MX337603B (es) 2009-11-30 2016-03-10 Adare Pharmaceuticals Inc Composiciones y tabletas farmaceuticas con recubrimiento compresible y metodos de fabricacion.
PH12012502139A1 (en) * 2010-04-27 2022-03-21 Bayer Ip Gmbh Orally disintegrating tablet containing acarbose
NZ611467A (en) * 2010-12-02 2015-06-26 Aptalis Pharmatech Inc Rapidly dispersing granules, orally disintegrating tablets and methods
EP2704694A4 (en) * 2011-05-02 2014-11-19 Aptalis Pharmatech Inc RAPID DISSOLUTION TABLET COMPOSITIONS FOR VAGINAL DELIVERY
KR101285008B1 (ko) * 2012-04-18 2013-07-10 제일약품주식회사 저용량 엔테카비어의 경구투여 제제의 제조방법
CN102784126A (zh) * 2012-08-23 2012-11-21 海南卫康制药(潜山)有限公司 利福平组合物冻干口腔崩解片及其制备方法
CN102784117A (zh) * 2012-08-23 2012-11-21 海南卫康制药(潜山)有限公司 硫酸庆大霉素组合物冻干口腔崩解片及其制备方法
CN102784121A (zh) * 2012-08-23 2012-11-21 海南卫康制药(潜山)有限公司 左氧氟沙星组合物冻干口腔崩解片及其制备方法
WO2014144512A1 (en) 2013-03-15 2014-09-18 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
GR1008992B (el) * 2015-12-17 2017-03-23 Verisfield (Uk) Ltd, Υποκαταστημα Ελλαδας, Εμπορια Φαρμακων Φαρμακευτικη συνθεση σε μορφη κοκκιων για χορηγηση απο το στομα που περιεχει μετρονιδαζολη ή παραγωγα αυτης και εναν παραγοντα καλυψης της γευσης
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
US20180256515A1 (en) 2017-03-10 2018-09-13 Adare Pharmaceuticals, Inc. Oral amphetamine composition
AU2018255718A1 (en) 2017-04-20 2019-12-05 Zeenar Enterprises Pty Ltd Fast disintegrating tablet
WO2018191794A1 (en) 2017-04-20 2018-10-25 Zeenar Enterprises Pty Ltd Liquid crystalline dosage form for administering a statin
CN111670050A (zh) 2018-01-30 2020-09-15 爱普宁公司(特拉华) 用于治疗睡眠呼吸暂停的方法和组合物
CN110840850B (zh) * 2018-07-24 2023-03-17 烟台药物研究所 一种高生物利用度的塞来昔布冻干口崩片及其制备方法
EP3870155A4 (en) * 2018-10-25 2023-08-09 Zeenar Enterprises Pty Ltd COMPOSITION FOR FORMING LIQUID CRYSTALLINE PARTICLES
ES3049086T3 (en) * 2019-02-08 2025-12-12 Brigham & Womens Hospital Inc Methods and compositions for treating sleep apnea
FR3099881B1 (fr) 2019-08-13 2022-08-26 Ethypharm Sa Comprimé orodispersible d’opioide à faible dosage et son procédé de préparation.
US12691128B2 (en) 2019-10-01 2026-07-28 Ellodi Pharmaceuticals, L.P. Methods of treating eosinophilic esophagitis and reducing candidiasis
CN110742868A (zh) * 2019-11-20 2020-02-04 合肥拓锐生物科技有限公司 一种Mirogabalin Besilate口腔崩解片
EP4729048A1 (en) * 2024-10-15 2026-04-22 Neuraxpharm Pharmaceuticals, S.L. Orally dispersible tablets of oxazepam

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4662880A (en) * 1986-03-14 1987-05-05 Alza Corporation Pseudoephedrine, brompheniramine therapy
US5629310A (en) * 1986-09-23 1997-05-13 Sterling; William R. Low dose temazepam
PT1121103E (pt) * 1998-05-18 2007-02-28 Takeda Pharmaceutical Comprimidos de desintegração oral compreendendo um benzimidazole
JP4739217B2 (ja) * 2003-05-07 2011-08-03 サムヤン コーポレイション 速く溶ける錠剤を製造するための高可塑性顆粒
GB0420016D0 (en) * 2004-09-09 2004-10-13 Leuven K U Res & Dev Controlled release oral delivery system
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
WO2006133349A2 (en) * 2005-06-08 2006-12-14 Alpharma, Inc. Orally disintegrable sleep aid formulations
JP5433236B2 (ja) * 2006-01-27 2014-03-05 アプタリス ファーマテック，インコーポレイテッド 弱塩基性選択性セロトニン５−ｈｔ３遮断剤および有機酸を含む薬物送達系

Also Published As

Publication number Publication date
CO6280465A2 (es) 2011-05-20
BRPI0821761A2 (pt) 2015-06-16
CN101925349A (zh) 2010-12-22
RU2524638C2 (ru) 2014-07-27
WO2009086046A1 (en) 2009-07-09
CL2008003827A1 (es) 2009-07-24
US20090169620A1 (en) 2009-07-02
RU2010130340A (ru) 2012-01-27
CN105496978A (zh) 2016-04-20
AR069875A1 (es) 2010-02-24
KR20100103844A (ko) 2010-09-28
RU2014106871A (ru) 2015-08-27

Similar Documents

Publication Publication Date Title
CL2013001586A1 (es) Composicion microgranular de rapida dispersion que comprende al menos un alcohol de azucar, un sacarido, o una mezcla de estos, al menos un super disgregante y al menos un aditivo multifuncion; comprimido de desintegracion oral que comprende la composicion microgranular y al menos un principio activo; y metodos de fabricacion.
CR10730A (es) Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
GT200800276A (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
BRPI0820997A2 (pt) Comprimidos de desintegração oral compreendendo difenidramina.
MX2010003299A (es) Oligonucleotidos muy cortos (micromirs).
CR20110186A (es) Formulación farmacéutica 514
GEP20135803B (en) Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
AR069875A1 (es) Composiciones de temazepam para tabletas de desintegracion oral y metodo de preparacion
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
BRPI0413361B8 (pt) comprimido seguro contra abuso termo-moldado por extrusão sem descoramento
BRPI0606339A2 (pt) formas farmacêuticas resistentes a álcool
CR11292A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
GT200900095A (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hermatologicas.
EP3272337A3 (en) Tablets
CO6400186A2 (es) Tabletas de acetato de ulipristal
WO2010038237A3 (en) Compositions exhibiting delayed transit through the gastrointestinal tract
CR9525A (es) Algodon insecticida ce43-67b
BRPI0916936A2 (pt) composições faramacêuticas e métodos para produzir baixas concentrações de impureza da mesmas.
CR9114A (es) 2-alcoxi-3,4,5-trihydroxi-alquimidas, su preparacion composicones que las contienen y su utilizacion
EA201070484A1 (ru) Новые конъюгаты нейртурина для фармацевтического применения
IN2012DN03096A (es)
PA8846401A1 (es) Sinergismo antibiótico
ES2395740T8 (es) Composiciones que comprenden estroncio y usos de las mismas en el tratamiento o prevención de la gingivitis, la periodontitis, la periodontitis como una manifestacioón de enfermedades sistémicas y las enfermedades peridontales necrotizantes
CL2007002981A1 (es) Composicion farmaceutica que contiene 75 mg del isomero dextrogiro de clopidogrel y 300 mg de triflusal, util en el tratamiento de enfermedades tromboembolicas.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)